Veracyte, Inc. reported $562M of revenue over the trailing twelve months, +17% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $562M (to Q2 2026). Net income: $114M, trailing twelve months to Q2 2026. Free cash flow: $166M, trailing twelve months to Q2 2026. Operating margin: 19%, trailing twelve months to Q2 2026.

VCYTVeracyte, Inc.

Healthcare

$45.23+33% 1Y

$45.23

$30.0152 weeks$59.55

VCYT as reported

Veracyte, Inc. reported $562M of revenue over the trailing twelve months, +17% on the year before. 11 reported series are charted on this page, each one as filed.

$562M

Revenue, trailing twelve months · to Q2 2026 · +17% against the twelve months before

Net income: $114M
Net income · +335% year on year · trailing twelve months to Q2 2026
Free cash flow: $166M
Free cash flow · +98% year on year · trailing twelve months to Q2 2026
Operating margin: 19%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VCYT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$562M	+17%	Q2 2026
Net income	$114M	+335%	Q2 2026
EPS	$1.40	+324%	Q2 2026
Gross margin	72%	n/a	Q2 2026
Operating margin	19%	n/a	Q2 2026
Net margin	20%	n/a	Q2 2026
ROE	5.6%	n/a	Q2 2026
ROA	5.2%	n/a	Q2 2026
ROIC	−4.3%	n/a	Q4 2022 · 14 quarters behind
Free cash flow	$166M	+98%	Q2 2026
P/E	32.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.